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Abstract: The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) caused an ongoing 
unprecedented global public health crises of coronavirus disease in 2019 (CoVID-19). The 
precipitously increased death rates, its impact on livelihood and trembling economies warrant the 
urgent development of a SARS-CoV-2 vaccine which would be safe, efficacious and scalable. Owing 
to unavailability of the vaccine, we propose a de novo synthesized avian orthoavulavirus 1 (AOaV-
1)-based topical respiratory vaccine candidate against CoVID-19. Avirulent strain of AOaV-1 was 
engineered to express full length spike (S) glycoprotein which is highly neutralizing and a major 
protective antigen of the SARS-CoV-2. Broad-scale in vitro characterization of a recombinant 
vaccine candidate demonstrated efficient co-expression of the hemagglutinin-neuraminidase (HN) 
of AOaV-1 and S protein of SARS-CoV-2, and comparable replication kinetics were observed in a 
cell culture model. The recombinant vaccine candidate virus actively replicated and spread within 
cells independently of exogenous trypsin. Interestingly, incorporation of S protein of SARS-CoV-2 
into the recombinant AOaV-1 particles attributed the sensitivity to anti-SARS-CoV-2 antiserum and 
more prominently to anti-AOaV-1 antiserum. Finally, our results demonstrated that the 
recombinant vaccine vector stably expressed S protein after multiple propagations in chicken 
embryonated eggs, and this expression did not significantly impact the in vitro growth 
characteristics of the recombinant. Taken together, the presented respiratory vaccine candidate is 
highly attenuated in primates per se, safe and lacking pre-existing immunity in human, and carries 
the potential for accelerated vaccine development against CoVID-19 for clinical studies. 
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1. Introduction 
An outbreak of pneumonia erupted in a Chinese seafood market in Wuhan during late 2019 and 
within a month of its origin, on 30 January 2020, a Public Health Emergency of International Concern 
was declared by the World Health Organization (WHO) due to its high human-to-human 
transmission. Within the next month, the outbreak of coronavirus disease in 2019 (CoVID-19) soared 
among communities unprecedentedly and spread across the globe and a pandemic was declared on 
11 March 2020 by the WHO. A large proportion (~80%) of CoVID-19 infected patients showed only 
moderate symptoms which led to a staggering rate increase in the global spread of the infection. The 
acute respiratory distress syndrome, manifested in ~20% of CoVID-19 patients, causing substantial 
case fatality rates especially in elderly and frail people with co-morbidities [1,2]. 
The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the causative agent of the 
ongoing CoVID-19 pandemic, belongs to the family Coronavirdae within the Betacoronavirus (b-CoV) 
genus. Similar to SARS-CoV and Middle Eastern respiratory syndrome-related coronavirus (MERS-
CoV), SARS-CoV-2 carries a single stranded linear RNA genome with positive polarity [3]. The 
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genome consists of four structural proteins including envelope (E), spike (S), membrane (M), and 
nucleocapsid (N), 16 non-structural proteins (nsp 1–16) and multiple accessary proteins. Amongst 
these viral proteins, the S protein constitutes a major protective antigen that elicits highly specific 
antibodies mediated immune responses [3]. Therefore, the S protein remained the primary vaccine 
markers against coronaviruses. 
Currently, there is no registered drug or vaccine available to curb the pandemic; however, 
multiple vaccines using a range of technologies are being developed, or pre-clinically or clinically 
being investigated [4]. Amongst these, an inactivated vaccine has elicited strong antibodies which 
can neutralize multiple SARS-CoV-2 strains and can partially or fully protect macaques against 
SARS-CoV-2 challenge [5]. A chimpanzee adeno (ChAd)-vectored vaccine, expressing the full-length 
S gene of SARS-CoV-2, elicited humoral and cell-mediated responses in rhesus macaques [6]. 
However, it failed to fully alleviate clinical signs in vaccinated macaques albeit reduced severity and 
protection against pneumonia. The ChAdOx1 nCoV-19 also failed to reduce the viral replication in 
the nose, highlighting the potential spread of SARS-CoV-2 through sneezing even in vaccinated 
people [6]. Recently, clinical data demonstrated the induction of antibodies and T-cell responses in 
humans by both ChAdOx1 and adjuvanted killed vaccines [7–9]. Several novel mRNA and DNA 
vaccines are being trialed with promising early results in pre-clinical and clinical studies [10,11]. 
However, it remains to be determined if these immune responses protect vaccinated individuals 
against natural SARS-CoV-2 infection. 
Owing to multifaceted advantages, the avian orthoavulavirus 1 (AOaV-1) proposes a potential 
vaccine vector against SARS-CoV-2. Specifically, AOaV-1 (represented by a type species, Newcastle 
disease virus, NDV) are exclusively cytoplasmic viruses and therefore the viral gene segments are 
not integrated into the host genome which raises their safety profile. Since these vectors lack natural 
recombination, the expression of transgenes is genetically stable. Additionally, AOaV-1 can infect 
multiple species of animals; the vaccines can be produced in chicken embryonated eggs and multiple 
cell lines using protocols and infrastructure currently being applied for influenza virus vaccines [12]. 
Given these and other features, apathogenic strains of AOaV-1 have been used as live attenuated 
vaccines against multiple viruses including influenza, SARS, human immunodeficiency virus [13,14], 
human parainfluenza, rabies [15], Nipah disease [16], Rift Valley fever [17], Ebola and highly 
pathogenic H5N1 [18,19]. Importantly, AOaV-1 has appeared to be safe and effective in mice [19], 
dogs [15], pigs [16], cattle [20,21], sheep [20], African green and rhesus monkeys [22,23] and humans 
[24–27]. Notably, the natural hosts of AOaV-1 are birds and the vector is antigenically distinct from 
common human pathogens. Therefore, no pre-existing immunity exists in humans which makes it an 
ideal vector to deliver transgene effective and safely. 
In the present study, we de novo designed an AOaV-1 vector and generated a recombinant 
vaccine candidate by expressing full-length codon-optimized S protein of the SARS-CoV-2 at a pre-
optimized gene junction. This topical respiratory vaccine candidate was fully characterized in vitro. 
Based on the infection and spreadability within cells, its sensitivity to anti-AOaV-1 and anti-SARS-
CoV-2 neutralizing antibodies, its replication kinetics and stability in chicken embryonated eggs, the 
rAOaV-1-SARS-CoV-2 is a scalable topical vectored vaccine candidate against SARS-CoV-2 to be 
tested for safety and immunogenicity in animal studies. 
2. Materials and Methods  
2.1. Cells and Viruses 
The AOaV-1-wt vaccine vector was rescued as described previously [28], passaged twice on 
African green monkey kidney (VERO) cells, and in embryonated chicken eggs. Vero cell line was 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). These cells were 
grown in Dulbecco’s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS). 
Fertile embryonated chicken eggs were purchased from Henry Stewart & Co Ltd., Fakenham, UK. 
2.2. Generation of Recombinant AOaV-1 Expressing S Protein of SARS-CoV-2 
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The genome of AOaV-1 encodes six structural genes in the order of nucleocapsid (N), 
phosphoprotein (P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN) and RNA dependent 
RNA polymerase (RdRP, also known as L). The transcription of the linear gene starts from gene start 
(GS) and ends at the gene-end (GE). Between the GS and GE, there is an intergenic sequence (IG). The 
foreign gene can be inserted at any of the gene junction (IG) with variable levels of transcription; 
however, recent studies have assessed optimal gene expression when inserted between P and M gene 
[14,28–30]. This arrangement of the gene is identical among all AOaV-1s. 
In order to offer a competitive reverse genetic system as a novel vaccine vector, an avirulent 
strain of AOaV-1 was used carrying a lentogenic-like cleavage site and pathogenicity (patent pending 
on the technology). The full length antigenomic sequence of AOaV-1, originally isolated from 
asymptomatic wild birds, was partially de novo synthesized (NBS Biologicals, Huntingdon, UK) 
using a novel sequence modification approach. Rest of the genome length mainly constituting around 
the P gene was cloned using overlapping PCRs. The entire cassette was then shuttled into the TVT7R 
(0,0) (Addgene Plasmid #98631). In order to avoid incorporation of extra non-viral gene residues into 
the transcribed minigenome and efficient transcription of the gene, an autocatalytic and “rule of six” 
adhered HHRz was introduced at the 5′-end and hepatitis delta virus ribozyme (HdvRz) at the 3′ end 
of the antigenome. 
An expression cassette for the full-length S gene was first in silico generated, containing the 
Kozak sequence, GE, GS, IG and the ORF for the full length S gene was codon-optimized for Homo 
sapiens codon-usage and inserted into the unique PmeI site between the P and M genes, which was 
originally preserved during the cloning of complete antigenome. The construct was named rAOaV-
1-SARS-CoV-2 whereas the AOaV-1 without the insertion of the foreign gene (AOaV-1-wt) was used 
as infection control throughout the study. The orientation of the inserted S gene was confirmed by 
the nucleotide sequence analysis at the time of cloning as well as during the propagation of the vector 
in cells and chicken embryonated eggs. 
The rAOaV-1-SARS-CoV-2 and AOaV-1-wt were used to rescue the infectious viruses as 
described previously [28] with substantial modifications. Briefly, Vero cells were infected with 
modified vaccinia Ankara (MVA) expressing the T7 polymerase at a multiplicity of infection 1.0 for 
6 hours. These cells were transfected with Lipofectamine 2000 using rAOaV-1-SARS-CoV-2 and 
AOaV-1-wt backbones as well as supporting N, P and L gene-expression plasmids (ratio of 
1:0.8:0.4:0.1) for 72 hours. After 3 days post-infection, cells and cell supernatants were mixed and 
freeze-thawed three times at –80 °C before inoculation into 8-day-old embryonated chicken eggs. 
After an additional three days, individual eggs were screened using hemagglutination assay and real-
time PCR as we described before [31–33]. Successfully rescued isolates were further propagated to 
generate viral stock and for in vitro characterization. 
2.3. Propagation of Viruses in Eggs and Cells  
The infectivity of the recombinant virus and parental wild type strains were characterized using 
a standard hemagglutination assay (HA). The 50% tissue infectious dose (TCID50) assay on Vero cells 
in 96-well plates, was performed and calculated following standard procedures [31,32,34]. 
2.4. Western Blotting 
To confirm expression of the viral protein, Vero cells were infected with recombinant and wild 
type viruses at a multiplicity of infection (MOI) of 0.1 as we described earlier [35]. Cell lysates were 
collected at 24 h post infection and subjected to Western blot. Briefly, after 24 h post-infection, cells 
were washed once with phosphate buffered saline (PBS) followed by adding 100 µL ice-cold NP40 
lysis buffer (completed with protease inhibitors cocktail) per well and incubated for 30 min on ice. 
All cell lysates were denatured at 98 °C for 8 min, proteins were separated by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), and subsequently transferred to 
nitrocellulose membranes [35]. The cell lysates were subjected for centrifugation at 13,000 rpm for 30 
min at 4 °C and the supernatants were incubated in sample loading buffer 2× (Biorad) containing 10% 
β-mercaptoethanol for 5 min at 98 °C, and separated on a 10% sodium dodecyl sulfate–
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polyacrylamide gel electrophoresis (SDS-PAGE), and proteins were transferred onto polyvinylidene 
difluoride (PVDF) membranes. The S and HN viral proteins were detected by incubation with 
primary antibodies (1:500 dilution). After probing with primary antibodies, the blots were incubated 
with peroxidase-conjugated species-specific secondary antibodies (Abcam, Cambridge, MA, USA) 
and visualized by chemiluminescence (Chemidoc, BioRad, Hercules, CA, USA), as we performed 
earlier [35]. 
2.5. Immunofluorescence 
The expression of the S and HN proteins in recombinant virus-infected cells were evaluated by 
immunofluorescence assays using confocal microscopy. Vero cells grown on coverslips in 24-well 
plates were infected with wild type or recombinant viruses or viruses pre-incubated with antisera for 
24 h. After fixing the cells with 4% paraformaldehyde in PBS for 30 min, washed with PBS, and 
permeabilized with 0.1% Triton X-100 for 10 min. After blocking of the cells with 5% bovine serum 
albumin (BSA) in PBS, they were incubated with monoclonal antibody (mAb) [36] to probe HN or S 
or both proteins. Binding of primary antibodies were visualized using Alexa 488 α-rabbit and 568 α-
mouse secondary antibodies (Invitrogen, Loughborough, UK). The S and HN proteins expression 
were analyzed through fluorescence for wild-type and recombinant viruses compared to mock 
infected cells. The 4′,6-diamidino-2-phenylindole (DAPI) was used to stain cell nuclei and the images 
were captured using a Zeiss confocal laser-scanning microscope (Zeiss, Kohen, Germany). Digital 
images were processed using Adobe illustrator software, and the same parameters were applied to 
the whole image area. 
2.6. Sensitivity of rAOaV-1-SARS-CoV-2 and AOaV-1-wt to Antisera 
A total of 5 × 102 TCID50 of AOaV-1-wt and rAOaV-1-SARS-CoV-2 was mixed with either anti-
AOaV-1 sera (heat-inactivated and diluted to 1:100) or mouse SARS-CoV-2 anti-sera (dilution 1:10) 
or with plain mouse anti-sera as mock neutralization. These mixtures were incubated for 1 hour at 37 
°C before infection of Vero cells grown on coverslips in 24-wells plates. After 1 hour of adsorption, 
the supernatant was removed, and cells were washed three times with PBS and supplemented with 
DMEM without serum. After 24 hours post-infection, cells were fixed with paraformaldehyde and 
immunofluorescence staining was performed using anti-HN antibodies against AOaV-1 as described 
above. Images were captured using a Zeiss confocal laser-scanning microscope (Zeiss, Kohen, 
Germany) and processed using Adobe illustrator software using identical parameters on all frames. 
2.7. Stability and Growth Characteristics of NDV Constructs Using Real-Time PCR 
The stability of recombinant vaccine candidate compared to parental wild type was grown 
sequentially in embryonated chicken eggs for at least 5 passages. RNA was extracted from the 
allantoic fluid of recombinant and wild type after the first and fifth passages in eggs using the 
QIAamp Viral RNA Mini Kit (Qiagen, Manchester, UK). The real-time qRT-PCR was performed 
using SuperScript III Platinum One-Step qRT-PCR Kit to detect the NDV M gene [33], which enabled 
the calculation of viral genome copies that was plotted against hours post-infection for each of the 
viruses to produce standard curves. To investigate the growth properties of the recombinant viruses, 
Vero cells were infected in 6-well plates at a MOI of 0.1 after being washed twice with PBS and an 
adsorption time of 60 min. Cell supernatants were harvested 0, 6, 12, 24 and 48 h post infection (p.i). 
Viral titers (50% tissue culture infectious dose, TCID50) were calculated by immunofluorescence assay 
(IFA) using primary antibodies against viral proteins and Alexa Fluor 488 α-rabbit and Alexa Fluor 
586 α-mouse as secondary antibodies (Invitrogen), respectively. 
2.8. Statistical Analysis 
Virus-infected and control groups were compared using Student’s t-test. All statistical analyses 
and figures were conducted in the GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
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3. Results 
3.1. Design and Construction of AOaV-1-SARS-CoV-2 Vaccine Candidate 
An avirulent strain of AOaV-1 was used to construct a vaccine candidate against SARS-CoV-2. 
The full length antigenomic sequence of AOaV-1, originally isolated from asymptomatic wild birds, 
was de novo synthesized. To facilitate minigenome transcription, an autocatalytic and “rule-of-six” 
adhered hammerhead ribozyme sequence was introduced in both 5′ and 3′-ends of the antigenome 
(Figure 1A). 
An expression cassette containing the Kozak sequence, GE, GS, IG and the ORF for the full-
length S gene was codon-optimized for Homo sapiens codon usage and inserted into the unique PmeI 
site between the P and M genes, which was originally preserved during the cloning of complete 
antigenome (Figure 1A). The construct was named rAOaV-1-SARS-CoV-2 whereas the AOaV-1 
without the insertion of the foreign gene (AoaV-1-wt) was used as infection control throughout the 
study. The orientation of the inserted S gene was confirmed by the nucleotide sequence analysis. 
3.2. Rescue of Recombinant Vaccine and Evaluation of the Spike Gene Expression of SARS-CoV-2 
The rAOaV-1-SARS-CoV-2 and AOaV-1-wt were rescued in Vero cells and propagated in 8-day-
old embryonated chicken eggs. Screening of multiple individually inoculated eggs, using real-time 
PCR and hemagglutination assays, has successfully identified rescued rAOaV-1-SARS-CoV-2 viruses 
(Figure S1 Supplementary) which were used to fully characterize in the presented study. 
Expression of the S protein was confirmed by indirect confocal immunofluorescent staining of 
rAOaV-1-SARS-CoV-2-infected Vero cells. Counter-staining of the HN protein of AOaV-1 and S 
protein of SARS-CoV-2 confirmed co-expression of the surface protein in rAOaV-1-SARS-CoV-2-
infected Vero cells, whereas only HN protein expression was observed in AOaV-1-wt-infected cells 
(Figure 1B). Graphical profile of the expression intensities confirmed co-expression of both surface 
proteins (Figure 1C) where a vast majority of rAOaV-1-SARS-CoV-2-infected cells expressed both 
HN and S proteins simultaneously (Figure 1D).  
Both recombinant and wild type AOaV-1 isolates replicated at high titer in eggs (≥28 HAU/ml). 
The evaluation of the viral replication in the presence of exogenous proteases in Vero cells indicated 
that rAOaV-1 expressing codon optimized S gene replicated at the level comparable to wild type 
AOaV-1 (Figure 1E). The expression analysis of the S protein by Western blot indicated a potent 
expression of the full-length S protein in rAOaV-1-SARS-CoV-2-infected cells whereas expression of 
the HN proteins was detected in both recombinant and wt AOaV-1-infected cells (Figure 1F). These 
results confirm that the expression of the transgene (S) did not interfere with the growth 
characteristics of the AOaV-1 and could be a replication competitive vaccine candidate. 
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Figure 1. Construction, rescue and characterization of rAOaV-1-SARS-CoV-2 vaccine candidate. (A) 
The full-length ORF for S gene of SARS-CoV-2 was over-hanged with required transcriptional signals 
(GE, GS, IG) and inserted in between P and M genes. The rough gene size is mentioned below each 
gene, the division of the genome across the length and number of nucleotides in intergenic region is 
displayed at the top of the schema of the rAOaV-1 genome. (B) Vero cells were infected with the 
rAOaV-1-wt or rAOaV-1-SARS-CoV-2 and stained for the expression of the HN (red) or S (green) 
proteins. The co-expression of both surface proteins is colored yellow in combined images and was 
marked with the arrow. (C) Quantitative co-expression profile is marked with arrow and shown in 
the line chart. (D) A total of nine microscopic fields were scanned for the presence of HN or S or both 
proteins. A significantly higher proportion of HN+S expressing cells were identified. (E) A 
comparable replication of rAOaV-1-wt or rAOaV-1-SARS-CoV-2 in Vero cells indicating the 
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competitive replication of rAOaV-1 even after the expression of the foreign S gene. (F) Western blot 
analysis for the expression of the HN protein, indicating the active replication of the rAOaV-1 and S 
protein indicating the rAOaV-1-SARS-CoV-2, indicating the replication competence of the 
recombinant virus. Alpha tubulin was used as loading control. **** indicates statistically significant 
difference with p < 0.005, and ns indicates non-significant. 
3.3. Exogenous Trypsin Independent Growth Characteristics of Vaccine Construct 
To initiate virus replication, the F protein of the AOaV-1 has to be cleaved by cellular proteases22. 
In order to investigate the pre-requisite of exogenous trypsin-like extracellular proteases for the 
infectivity of AOaV-1, eggs-propagated rAOaV-1-SARS-CoV-2 and AOaV-1-wt were used to infect 
Vero cells with a multiplicity of infection (MOI) of 1.0 without exogenous trypsin treatment. As 
expected, the replication of rAOaV-1-SARS-CoV-2 was apparent 6 hours post-infection and the 
individually infected cells spread the infection to neighboring cells within the next 12 hours. At 2 
days post-infection, as high as 90% of the cells were infected with the rAOaV-1-SARS-CoV-2 and the 
majority of cells co-expressed HN protein of the AOaV-1 and S protein of the SARS-CoV-2 (Figure 
2A and Figure S2 Supplementary). Cumulative fluorescence dynamics, based on either HN or S 
protein expressions, over the course of the infection, confirmed a gradual spread of the infection 
(Figure 2B). Co-expression fluorescence profile highlighted the co-localization of both surface 
proteins (Figure 2C). Similar to recombinant AOaV-1, the AOaV-1-wt replicated to a similar extent 
over the course of two days post-infection without the need of exogenous extracellular proteases and 
saturated levels of expression of the HN protein was observed at 48 hours post-infection (Figure 2D 
and Figure 2 supplementary). The cumulative fluorescence dynamics (Figure 2E) and fluorescence 
profile (Figure 2F) confirmed the active and progressive expression and HN-specific staining, 
respectively. Taken together, these results confirm the active replication, and expression of AOaV-1 
and foreign genes in Vero cells independently of exogenous trypsin. 
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Figure 2. Replication of rAOaV-1-SARS-CoV-2 and AOaV-1-wt in mammalian cells. (A) Vero cells 
were infected with MOI of 1.0 with rAOaV-1-SARS-CoV-2. These cells were fixed with 
paraformaldehyde at 0, 6, 12, 24 and 48 hours post-infection and stained for the HN protein of rAOaV-
1 and S protein in the rAOaV-1-SARS-CoV-2. (B) Cumulative quantification of the green (S) and red 
(HN) fluorescence intensities before confocal microscopic imaging. (C) The co-expression profile for 
the HN and S proteins. (D) Vero cells were infected with MOI of 1.0 with rAOaV-1-wt. These cells 
were fixed with paraformaldehyde at 0, 6, 12, 24 and 48 hours post-infection and stained for the HN 
protein of rAOaV-1. (E) Cumulative quantification of the green (S) and red (HN) fluorescence 
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intensities before confocal microscopic imaging. (F) The co-expression profile for the HN and S 
proteins are graphically presented. 
3.4. The rAOaV-1-SARS-CoV-2 is Sensitive to AOaV-1 and SARS-CoV-2 Antisera 
The F and HN surface glycoproteins are critical for receptor binding as well as membrane fusion 
which are indispensable for virus entry and subsequent initiation of the virus replication [37,38]. In 
contrast, the coronaviruses have only a single enveloped glycoprotein, which performs dual 
functions of receptor binding and membrane fusion [39]. In order to understand the influence of the 
S protein of the SARS-CoV-2 on the infectivity of the recombinant virus, the sensitivities of AOaV-1 
and SARS-CoV-2 antisera were assessed and compared for neutralization. As expected, the AOaV-1-
wt was resistant to mock antiserum neutralization; however, it was almost fully neutralized by the 
serum against the AOaV-1 (Figure 3A). Quantitatively, the anti-AOaV-1 antiserum reduced the 
infection of AOaV-1-wt in Vero cells by ~92% compared to the mock-neutralization (Figure 3B). In 
contrast, neutralization analysis of the rAOaV-1-SARS-CoV-2 showed a significant blockage of the 
virus entry by pre-incubation and subsequent infection of rAOaV-1-SARS-CoV-2 with either anti-
AOaV-1 or anti-SARS-CoV-2 anti-sera (Figure 3C). There was no neutralization observed upon the 
virus’s treatment with the naïve mouse control serum. However, compared to mock-neutralization, 
a total of ~90% inhibition of the rAOaV-1-SARS-CoV-2 was observed with anti-AOaV-1 antiserum 
and ~40% inhibition was noticed with anti-SARS-CoV-2 anti-serum (Figure 3D). These observations 
confirm that the incorporation of S protein of SARS-CoV-2 into the recombinant AOaV-1 particles 
attribute to the sensitivity of the AOaV-1 to anti-SARS-CoV-2 antiserum and anti-AOaV-1 antiserum. 
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Figure 3. Sensitivity of recombinant and wild type (wt) viruses against antisera. (A) AOaV-1-wt virus 
was incubated with an antiserum against AOaV-1 for 2 hours or was incubated with plain antiserum. 
The Vero cells were then infected with these viruses and incubated for 24 hours before staining against 
the HN protein of AOaV-1. (B) The mock-neutralization was set to 100%, and the quantitative analysis 
of the virus replication was plotted for the AOaV-1 neutralized with antiserum. (C) rAOaV-1-SARS-
CoV-2 virus was incubated with an anit-AOaV-1 antiserum or SARS-CoV-2 antiserum for 2 hours 
before infection of Vero cells for another 24 hours. These cells were then stained for the expression of 
the HN glycoprotein of rAOaV-1-SARS-CoV-2. (D) Quantitative measurement of the staining 
intensities plotted against the mock-treated neutralization control. **** indicates statistically 
significant difference with p < 0.005, and ** indicates level of significance at p < 0.05. 
3.5. In Vitro Growth Characterization of the Vaccine Construct 
In order to understand the replication competence of rAOaV-1-SARS-CoV-2 and AOaV-1-wt, 
multistep growth kinetics was evaluated in Vero cells. The time-course quantitative measurement of 
the genomic copies confirmed that the expression of the S gene did not interfere with the viral 
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replication and the rAOaV-1-SARS-CoV-2 replicated competitively and comparability with the 
AOaV-1-wt (Figure 4A). The cell lysate from the same experimental setting was used to assess the 
expression of the AOaV-1 structural proteins. The expression analysis using Western blotting 
demonstrated that both AOaV-1-wt (Figure 4B) and rAOaV-1-SARS-CoV-2 (Figure 4C) progressively 
replicated in Vero cells and expressed the HN protein as early as 6 hours post-infection and as late as 
2 days after initiation of the infection. These results demonstrated that the expression of the foreign 
genes by the AOaV-1 was unable to further attenuate the replication of the virus and could yield into 
sufficient viral quantity in cell culture system. 
 
Figure 4. Growth kinetics of the rAOaV-1 SARS-CoV-2 vaccine and AOaV-1 wt constructs. (A) Vero 
cells were infected with an MOI 1.0 of rAOaV-1-SARS-CoV-2 or AOaV-1-wt for 2 hours (0 hour post 
infection) and were then replaced with media to be incubated and extraction of RNA at 6, 12, 24 and 
48 hours post infection. The viral copy numbers were calculated from AOaV-1 standard run in 
parallel. (B) Vero cells were infected with AOaV-1 and total cell lysate was prepared at indicated time 
points post-infection. These lysates were run for Western blotting using HN antibodies to 
demonstrate virus replication and alpha tubulin as loading control. (C) Similar to section B, cells were 
infected with rAOaV-1-SARS-CoV-2 and the expression for the HN and alpha tubulin was measured 
at indicated time points. 
3.6. Stability of Recombinant AOaV-1 SARS-CoV-2 Vaccine Candidate 
In order to assess the stability of the foreign gene in the recombinant AOaV-1, the recovered and 
S-gene expression-confirmed viruses were passaged in 8-day-old embryonated chicken eggs for five 
consecutive passages. Both rAOaV-1-SARS-CoV-2 and AOaV-1-wt replicated substantially in eggs 
(≥28 HAU/ml, data not shown). The comparative replication competence was assessed between first 
and fifth egg-passaged viruses in Vero cells. The rAOaV-1-SARS-CoV-2 expressing the S protein of 
the SARS-CoV-2 grew efficiently and at the level of the AOaV-1-wt in the first passage as well as after 
fifth passage in the embryonated eggs (Figure 5A). Correspondingly, the expression of the structural 
protein of the AOaV-1 further confirmed the stable propagation of the wt and recombinant viruses 
at least for several passages (Figure 5B). The sequence integrity of the inserted S gene as well as the 
P and M junction was assessed without any mutations. Additionally, sequencing of the S gene from 
the first and fifth passages confirmed no unwanted mutations in purified viruses. These results 
demonstrate that the rAOaV-1-SARS-CoV-2 expresses S gene stably and this expression did not 
significantly impact the in vitro growth characteristics of the recombinants. 
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Figure 5. Stability replication of AOaV-1 SARS-CoV-2 vaccine candidate in embryonated chicken 
eggs. (A) The rAOaV-1-SARS-CoV-2 as well as rAOaV-1-wt were propagated in eggs and were 
quantified in Vero cells. The titer quantification, as shown in the bar chart, represents comparable 
replication. Both rAOaV-1-SARS-CoV-2 and rAOaV-1-wt were consecutively propagated in chicken 
embryonated eggs for 5 passages and the virus titer was quantified in Vero cells. (B) The first and fifth 
passages for both rAOaV-1-SARS-CoV-2 and rAOaV-1-wt were used to infect Vero cells for 24 hours 
before cell lysis and expression analysis for the HN structural protein of the rAOaV-1. 
4. Discussion 
The precipitously increasing deaths, negative impact on lives and livelihood, and trembling 
economies warrant the urgent development of SARS-CoV-2 vaccine which would be safe, efficacious 
and scalable. Amongst experimental vaccines being presented for SARS-CoV-2, the vectored-based 
vaccines hold potential for an effective vaccine against CoVID-19 [4]. However, each viral vector 
inherits multiple advantages and disadvantages and careful consideration of gene delivery system 
may pave the way for an effective vaccine. 
We propose a pre-tested vaccine vector based on the recombinant apathogenic strain of AOaV-
1 (i.e., NDV). We engineered AOaV-1 to express the full-length S glycoprotein of SARS-CoV-2, which 
is a vital viral neutralization and major protective antigen of the virus [39]. Using exhaustive in vitro 
characterization of recombinant vaccine candidate, rAOaV-1-SARS-CoV-2 demonstrated efficient co-
expression of surface proteins of AOaV-1 and SARS-CoV-2 in the mammalian cell line. This host-
range restricting replication in mammals is one of the most attractive properties of AOaV-1 [40]. 
While the mechanism of host range-restriction needs investigation, it is known that AOaV-1 induces 
a strong interferon response in mammalian cells which in turn limits its replication [41,42]. 
Additionally, sialic acid receptors for the viral attachment might show fundamental differences 
between avian and mammalian hosts and thus defines the host restriction. It has been observed that 
bovine parainfluenza virus type 3, another paramyxovirus in the same family, determines the host 
range restriction through multiple viral proteins [43]. Notwithstanding, AOaV-1 are clearly highly 
restricted to primates and this selective replication is irrespective of any of the known pathotypes 
such as mesogenic or lentogenic strains of AOaV-1 [23].  
In addition to the above mentioned factors, the AOaV-1 carries a range of advantages over other 
multiple vectors. AOaV-1 are antigenically distinct from viruses that are known to naturally infect 
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humans and AOaV-1 does not show cross-reactivities with antibodies raised against other 
paramyxoviruses. Therefore, AOaV-1 induces strong immune responses in the human population. 
Pertinent to this feature and interferon sensitivity, AOaV-1 are considered a valuable oncolytic agent 
and thus propose safety in humans upon parenteral administration [44]; 
www.cancer.gov/cancertopics/pdq/cam/NDV/healthprofessional. Potential seroconversion and a 
transient conjunctivitis may occur in poultry health workers, which subsides within four days 
without any additional or systemic symptoms [45]. Altogether, AOaV-1 presents a pre-tested and 
proven safety profile in humans and may highlight speeding rolling out of the recombinant vaccines 
in the general human population. 
Majority of vaccines (i.e., recombinant protein-based) require tedious manufacturing procedures 
and are therefore resource demanding. On the other hand, preparation of inactivated whole virus 
SARS-CoV-2 vaccines require biosafety level (BSL)-3 facilities and due to limited BSL-3 facilities 
preparation of such vaccines are inconvenient [5,46]. The AOaV-1-based vectored vaccines propose 
solutions to the abovementioned limitation of subunit vaccines with high titer replication in chicken 
embryonated eggs which are low-resource demanding and may be scaled up in developing countries. 
Additionally, using the existing influenza virus vaccine production pipelines, AOaV-1-based 
vaccines can be manufactured under BSL-2 conditions. Importantly, our results also demonstrated 
that a AOaV-1-based CoVID-19 vaccine candidate can also be propagated in Vero cells which is a US 
FDA-approved cell line for human vaccine production.  
Similar to other paramyxoviruses, AOaV-1 enters host cells by direct fusion at the plasma 
membrane through a pH-independent mechanism [40,41]. The AOaV-1 can also enter host cells by 
an endocytic pathway. The entry of the AOaV-1 into the cell is then mediated by the surface fusion 
(F) glycoprotein, which is also a major determinant of AOaV-1 virulence in birds [42]. The viral 
infectivity requires cleavage of the F protein through the intracellular ubiquitous proteases including 
furin, allowing disseminated replication in multiple organs and tissues. By a mechanism similar to 
AOaV-1, rAOaV-1-SARS-CoV-2 enter the cells through proteolytic cleavage of the S protein [39]. The 
trypsin-independent infectivity of rAOaV-1-SARS-CoV-2, as was observed in our study, facilitated 
the vector propagation in the cell-culture model as well as embryonated chicken eggs. 
A wealth of data has been generated on the safety, efficacy and immune-regulatory properties 
of AOaVs as oncolytic agent in humans. Specifically, it has been demonstrated that AOaVs show 
profound stimulation of innate immunity and production of multiple cytokines, such as IFN-α, IFN-
β, TNFα and IL-1, which in turn activate NK cells, macrophages, and sensitized T cells [25,46–48]. 
Additionally, AOaVs are known to upregulate major histocompatibility complex (MHC) class I 
molecules and enhance T-cell co-stimulatory activities which results in enhanced effector cells [49,50]. 
A genetically modified AOaVs expressing human IL-2 resulted in the activation of cytotoxic T 
lymphocyte (CTL) and memory T cells [51]. Collectively, owing to pleiotropic immunostimulatory 
effects, T helper (TH) responses, and CTL, NK cells, and macrophages activation, AOaVs show 
promising safety and immunogenicity profiles as vaccine vector. 
It has previously been shown that insertion of the transgene may make the vector sensitive to 
neutralization by antibodies, which are specific to the inserted protein and may facilitate the seepage 
of neutralization by vector-specific neutralizing antibodies [52]. The rAOaV-1-SARS-CoV-2 expresses 
both the native structural HN protein as well as S glycoprotein and therefore the entry into the cell 
may be attributed to the AOaV-1-like or SARS-CoV-2-like property. In conjunction with this 
hypothesis, the anti-AOaV-1 antiserum, as well as the anti-SARS-CoV-2, could substantially block 
the entry of the rAOaV-1-SARS-CoV-2. Additionally, the recombinant AOaV-1-SARS-CoV-2 offers 
an exciting system to underpin functional interactions between native and foreign envelope 
glycoproteins in one viral particle.  
Recently, insertion of the foreign genes into the backbone of the AOaV-1 has been practiced for 
multiple viruses including influenza, SARS, human immunodeficiency virus [13], human 
parainfluenza, rabies [15], Nipah disease [16], Rift Valley fever [17], Ebola and highly pathogenic 
H5N1 [18,19]. In several studies, it has been demonstrated that insertion of the transgene into the 
genomes of AOaV-1 resulted in reduced pathogenicity in poultry birds. This safety was maintained 
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even after the expression of the HA gene from a highly pathogenic avian influenza virus [18,19]. 
Sustained, stable and progressive replication of both wt and recombinant viruses demonstrated 
effective independent spread within cells. 
5. Conclusions 
Taken together, our results demonstrated that the recombinant vector expressing S protein 
propagated stably in chicken embryonated eggs for several consecutive passages, and this expression 
did not significantly impact the in vitro growth characteristics of the recombinants. The presented 
respiratory vaccine candidate has the potential for further development as vaccine vector to be 
available for expedited vaccine development for pre-clinical and clinical studies. 
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(C) Quantitative presentation of rAOaV-1-wt or rAOaV-1-SARS-CoV-2 detection. (D) Hemagglutination assay 
used to screen the chicken embryonated eggs for the presence (+)/absence (–) of rAOaV-1-wt or rAOaV-1-SARS-
CoV-2, Figure S2: Replication of wt and recombinant viruses in Vero cells. (A) Comprehensive and expanded 
confocal microscopic images representing Figures 2A–C. (B) Comprehensive and expanded confocal 
microscopic images representing Figures 2D–F. 
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